Angiopep 2

TFFYGGSRGKRNNFKTEEY-acid

  • Description

  • Application Data

Description

Based on the Kinitz domain of human aprotinin. Binds to LRP1 and is able to cross the blood brain barrier

See full description

Application Data

Catalogue number crb1001191
Molecular Weight 2300.1
Sequence (one letter code)

TFFYGGSRGKRNNFKTEEY-acid

Sequence (three letter code)

H-Thr-Phe-Phe-Tyr-Gly-Gly-Ser-Arg-Gly-Lys-Arg-Asn-Asn-Phe-Lys-Thr-Glu-Glu-Tyr-OH

Purity >95%
Storage -20°C
References

Demeule et al. (2007). Identification and design of peptides as a new drug delivery system for the brain. J. Pharmacol. Exp. Ther. 324 1064. PMID: 18156463

 

Demeule et al. (2008). Involvement of the low-density lipoprotein receptor-related protein in the transcytosis of the brain delivery vector Angiopep-2. J Neurochem. 106(4) 1534. PMID: 18489712

 

Lu et al. (2017). Angiopep-2-conjugated poly(ethylene glycol)-co- poly(ε-caprolactone) polymersomes for dual-targeting drug delivery to glioma in rats. Int J Nanomedicine. 12 2117. PMID: 28356732

Manufactured in: United Kingdom
Data Sheet Data Sheet Data Sheet Material Safety Data Sheet (MSDS)

Part of the angiopep family of peptides which have been derived from the Kunitz domain of human aprotinin. These peptides are able to cross the blood brain barrier (BBB) and have been used to facilitate the delivery of pharmacological agents to the brain, for example to target glioblastoma tumours and recurrent brain metastases of pre-treated breast cancers. Angiopep-2 has higher transcytosis capacity and higher brain volume of distribution than aprotinin. Like aprotinin, angiopep-2 interacts with low-density lipoprotein receptor-related protein 1 (LRP1) which is thought to promote its delivery across the BBB via receptor-mediated transcytosis (RMT). However the interaction with LRP1 may not be the only method for angiopep-2 to cross into the brain.

Angiopep 2

Cat No.Pack SizePriceQty.
0.5mg£85.00
1mg£110.00
5mg£350.00
10mg£550.00
Bulk Quote